Marc D. Piroth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marc D. Piroth has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Michael Pinkawa
Department of Radiation Oncology, Wege Klinik, Bonn, Germany
11 shared publications - Michael J. Eble
Department of Radiation Oncology, RWTH Aachen University, 52074 Aachen, Germany
10 shared publications Michael J. Eble
RWTH Aachen University Hospital
6 shared publications- Richard Holy
Department of Radiation Oncology, RWTH Aachen University, Pauwelsstrasse 30, 52072 Aachen, Germany
6 shared publications - Bernd Gagel
Department of Radiotherapy, RWTH Aachen University, Germany
5 shared publications - Branka Asadpour
Department of Radiotherapy, RWTH Aachen University, Germany
5 shared publications
Latest Publications
- 27 October 2013
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 189 (12) , 1054-5
Risiken ungünstiger Kosmetik und Toxizität nach perkutaner akzelerierter Teilbrustbestrahlung (APBI)
- 27 October 2013
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 189 (12) , 1054-5
Risiken ungünstiger Kosmetik und Toxizität nach perkutaner akzelerierter Teilbrustbestrahlung (APBI)
- Open Access
- 1 May 2013
- Vol. 2 (2) , 114-115-115
Intraoperative radiotherapy of the breast - really a valide option or "only" comfortable
- 1 May 2013
- Vol. 2 (2) , 114-115-115
Open AccessIntraoperative radiotherapy of the breast - really a valide option or "only" comfortable
- Open Access
- 10 December 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 209
Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy
The outcome of patients after radiotherapy (RT) for localized prostate cancer in case of prostate-specific antigen (PSA) progression during primary hormonal therapy (HT) is not well known. A group of 27 patients presenting with PSA progression during primary HT for local prostate cancer RT was identified among patients who were treated in the years 2000–2004 either using external-beam RT (EBRT; 70.2Gy; n=261) or Ir-192 brachytherapy as a boost to EBRT (HDR-BT; 18Gy + 50.4Gy; n=71). The median follow-up period after RT was 68 months. Median biochemical recurrence free (BRFS), disease specific (DSS) and overall survival (OS) for patients with PSA progression during primary HT was found to be only 21, 54 and 53 months, respectively, with a 6-year BRFS, DSS and OS of 19%, 41% and 26%. There were no significant differences between different RT concepts (6-year OS of 27% after EBRT and 20% after EBRT with HDR-BT). Considering all 332 patients in multivariate Cox regression analysis, PSA progression during initial HT, Gleason score>6 and patient age were found to be predictive for lower OS (p0.5 ng/ml during initial HT were both significant risk factors for biochemical recurrence. An unfavourable prognosis after PSA progression during initial HT needs to be considered in the decision process before local prostate radiotherapy. Results from other centres are needed to validate our findings.
- 10 December 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 209
Open AccessLocal prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy
The outcome of patients after radiotherapy (RT) for localized prostate cancer in case of prostate-specific antigen (PSA) progression during primary hormonal therapy (HT) is not well known. A group of 27 patients presenting with PSA progression during primary HT for local prostate cancer RT was identified among patients who were treated in the years 2000–2004 either using external-beam RT (EBRT; 70.2Gy; n=261) or Ir-192 brachytherapy as a boost to EBRT (HDR-BT; 18Gy + 50.4Gy; n=71). The median follow-up period after RT was 68 months. Median biochemical recurrence free (BRFS), disease specific (DSS) and overall survival (OS) for patients with PSA progression during primary HT was found to be only 21, 54 and 53 months, respectively, with a 6-year BRFS, DSS and OS of 19%, 41% and 26%. There were no significant differences between different RT concepts (6-year OS of 27% after EBRT and 20% after EBRT with HDR-BT). Considering all 332 patients in multivariate Cox regression analysis, PSA progression during initial HT, Gleason score>6 and patient age were found to be predictive for lower OS (p0.5 ng/ml during initial HT were both significant risk factors for biochemical recurrence. An unfavourable prognosis after PSA progression during initial HT needs to be considered in the decision process before local prostate radiotherapy. Results from other centres are needed to validate our findings.
- 17 October 2012
- Published by Springer Nature in Breast Cancer
- Vol. 21 (4) , 409-414
Fat necrosis and parenchymal scarring after breast-conserving surgery and radiotherapy with an intraoperative electron or fractionated, percutaneous boost: a retrospective comparison
The aim of this retrospective analysis was to evaluate mammographic changes such as fat necroses and parenchymal scarring in the breast tissue within the first 3 years after breast-conserving surgery (BCS) and whole-breast irradiation with an additional intraoperative electron boost (IO-B) versus fractionated percutaneous boost (FP-B). A total of 53 breast cancer patients (stage I/II) treated between 2006 and 2008 were included. All patients underwent BCS followed by fractionated whole-breast radiotherapy with a total dose and single dose of 50.4 and 1.8 Gy. Twenty patients had 10 Gy IO-B using electrons, and 33 patients were treated with a FP-B with 10.8 Gy. The IO-B was performed using the mobile linear accelerator NOVAC 7. The follow-up mammograms were focused on fat necroses, parenchymal scarring and skin thickening. Fat necroses occurred significantly more frequently in IO-B patients compared to FP-B patients (50.0 vs. 18.2 %). The fat necroses were mammographically detected a median of 17 versus 23 months post-surgery for the IO-B versus FP-B patients. The median size of fat necroses was 24 (14–30) mm for the IO-B group and 14 (4–53) mm for the FP-B group. Parenchymal scarring in the grade 3–4 tumor bed area was seen significantly more frequently in the IO-B patients (55.0 vs. 21.2 %). Skin thickening did not differ significantly. The IO-B led to significantly more fat necroses and local restricted parenchymal scarring in our analysis.
- 17 October 2012
- Published by Springer Nature in Breast Cancer
- Vol. 21 (4) , 409-414
Fat necrosis and parenchymal scarring after breast-conserving surgery and radiotherapy with an intraoperative electron or fractionated, percutaneous boost: a retrospective comparison
The aim of this retrospective analysis was to evaluate mammographic changes such as fat necroses and parenchymal scarring in the breast tissue within the first 3 years after breast-conserving surgery (BCS) and whole-breast irradiation with an additional intraoperative electron boost (IO-B) versus fractionated percutaneous boost (FP-B). A total of 53 breast cancer patients (stage I/II) treated between 2006 and 2008 were included. All patients underwent BCS followed by fractionated whole-breast radiotherapy with a total dose and single dose of 50.4 and 1.8 Gy. Twenty patients had 10 Gy IO-B using electrons, and 33 patients were treated with a FP-B with 10.8 Gy. The IO-B was performed using the mobile linear accelerator NOVAC 7. The follow-up mammograms were focused on fat necroses, parenchymal scarring and skin thickening. Fat necroses occurred significantly more frequently in IO-B patients compared to FP-B patients (50.0 vs. 18.2 %). The fat necroses were mammographically detected a median of 17 versus 23 months post-surgery for the IO-B versus FP-B patients. The median size of fat necroses was 24 (14–30) mm for the IO-B group and 14 (4–53) mm for the FP-B group. Parenchymal scarring in the grade 3–4 tumor bed area was seen significantly more frequently in the IO-B patients (55.0 vs. 21.2 %). Skin thickening did not differ significantly. The IO-B led to significantly more fat necroses and local restricted parenchymal scarring in our analysis.
- 22 February 2012
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 188 (4) , 334-339
Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas
Dose escalations above 60 Gy based on MRI have not led to prognostic benefits in glioblastoma patients yet. With positron emission tomography (PET) using [18F]fluorethyl-L-tyrosine (FET), tumor coverage can be optimized with the option of regional dose escalation in the area of viable tumor tissue.
- 22 February 2012
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 188 (4) , 334-339
Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas
Dose escalations above 60 Gy based on MRI have not led to prognostic benefits in glioblastoma patients yet. With positron emission tomography (PET) using [18F]fluorethyl-L-tyrosine (FET), tumor coverage can be optimized with the option of regional dose escalation in the area of viable tumor tissue.
- 2 February 2012
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 103 (2) , 247-251
Urinary morbidity after permanent prostate brachytherapy – Impact of dose to the urethra vs. sources placed in close vicinity to the urethra
- 2 February 2012
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 103 (2) , 247-251
Urinary morbidity after permanent prostate brachytherapy – Impact of dose to the urethra vs. sources placed in close vicinity to the urethra
- Open Access
- 30 January 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 14
Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without 18F-choline PET-CT detected simultaneous integrated boost
In comparison to the conventional whole-prostate dose escalation, an integrated boost to the macroscopic malignant lesion might potentially improve tumor control rates without increasing toxicity. Quality of life after radiotherapy (RT) with vs. without 18F-choline PET-CT detected simultaneous integrated boost (SIB) was prospectively evaluated in this study.
- 30 January 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 14
Open AccessDose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without 18F-choline PET-CT detected simultaneous integrated boost
In comparison to the conventional whole-prostate dose escalation, an integrated boost to the macroscopic malignant lesion might potentially improve tumor control rates without increasing toxicity. Quality of life after radiotherapy (RT) with vs. without 18F-choline PET-CT detected simultaneous integrated boost (SIB) was prospectively evaluated in this study.
- 1 May 2011
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 99 (2) , 218-224
Prognostic impact of postoperative, pre-irradiation 18F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy
- 1 May 2011
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 99 (2) , 218-224
Prognostic impact of postoperative, pre-irradiation 18F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy
- Open Access
- 8 April 2010
- Published by Springer Nature in Radiation Oncology
- Vol. 5 (1) , 27
Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study
To answer the question if and to which extent acute symptoms at the end and/or several weeks after radiotherapy can predict adverse urinary and gastrointestinal long-term quality of life (QoL).
- 8 April 2010
- Published by Springer Nature in Radiation Oncology
- Vol. 5 (1) , 27
Open AccessConsequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study
To answer the question if and to which extent acute symptoms at the end and/or several weeks after radiotherapy can predict adverse urinary and gastrointestinal long-term quality of life (QoL).